小干扰RNA降血脂药英克司兰研究进展  

Small Interfering RNA Lipid-Lowering Drug of Inclisiran

作　　者：乔斌超 贾永平[2] QIAO Binchao;JIA Yongping(The First Clinical Medical College of Shanxi Medical University,Taiyuan 030001,Shanxi,China;Department of Cardiology,The First Hospital of Shanxi Medical University,Taiyuan 030001,Shanxi,China)

机构地区：[1]山西医科大学第一临床医学院,山西太原030001 [2]山西医科大学第一医院心内科,山西太原030001

出　　处：《心血管病学进展》2024年第6期525-528,共4页Advances in Cardiovascular Diseases

摘　　要：英克司兰是一种新型的小干扰RNA降血脂药,通过靶向递送至肝脏,在肝细胞内特异性抑制前蛋白转化酶枯草溶菌素9的合成,从而降低低密度脂蛋白胆固醇水平。目前美国食品药品监督管理局和国家药品监督管理局已经正式批准英克司兰上市。现从英克司兰的作用机制、临床应用有效性及安全性等方面进行综述,以期为降脂治疗提供参考。Inclisiran is a novel small interfering RNA lipid-lowering drug that through targeted delivery to the liver,specifically inhibits the synthesis of the proprotein convertase subtilisin/kexin type 9 in liver cells,thereby reducing low-density lipoprotein cholesterol levels.At present,the Food and Drug Administration and the National Medical Products Administration have officially approved the marketing of inclisiran.This article provides a review of the mechanism,clinical application efficacy and safety of inclisiran,in order to provide reference for lipid-lowering treatment.

关 键 词：小干扰RNA 英克司兰 前蛋白转化酶枯草溶菌素9 低密度脂蛋白胆固醇 

分 类 号：R972.6[医药卫生—药品]